Brainstorm Cell Therapeutics BCLI
OTC BCLI
$0.95 -0.04 (-4.04%)
At close: Nov 11, 2026 · 4:00 PM EST

Brainstorm Cell Therapeutics (BCLI) Income from Discontinued Operations (2009 - 2010)

Updated

Analysis

Brainstorm Cell Therapeutics (BCLI) Income from Discontinued Operations (2009 - 2010) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Brainstorm Cell Therapeutics 10.92 Mn 10.85 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2010 164,000.00
Dec 31, 2009 -328,000.00
Sep 30, 2009 164,000.00
Jun 30, 2009 164,000.00
Mar 31, 2009 164,000.00
API Access

Brainstorm Cell Therapeutics Income from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-discontinued-operations&ticker=BCLI&period=max&api_key=YOUR_API_KEY